Aardvark Therapeutics Faces Major Investor Concern After Dramatic Stock Fall
Aardvark Therapeutics Faces Investor Scrutiny After Major Stock Drop
On March 2, 2026, Aardvark Therapeutics (NASDAQ: AARD) faced a severe blow when its stock price plummeted by $7.02, resulting in a staggering 56% drop. This dramatic fall followed the company's announcement regarding the abrupt halt of its Phase 3 clinical trial for the drug ARD-101, aimed at treating hyperphagia associated with Prader-Willi Syndrome (PWS).
The
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.